Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
10 Biggest Biotechnology Companies
11:32pm, Thursday, 30'th Jul 2020
With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for
04:33pm, Tuesday, 28'th Jul 2020
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals Wins FDA Approval for Its New Narcolepsy Drug
05:49pm, Wednesday, 22'nd Jul 2020
Xywav has been shown to reduce both cataplexy and excessive daytime sleepiness in narcolepsy patients.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Insiders Increased Their Holdings
12:45pm, Wednesday, 22'nd Jul 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21
Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020
08:05pm, Tuesday, 21'st Jul 2020
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020, after the close of the financial markets. Company mana
Assessing An Investment In Avadel Pharmaceuticals
12:51pm, Thursday, 16'th Jul 2020
Today, we take an in-depth look at Avadel Pharmaceuticals which recently sold off its existing product portfolio.
National Comprehensive Cancer Network® adds Zepzelca™ (lurbinectedin) to Clinical Practice Guidelines in Oncology
12:00pm, Monday, 13'th Jul 2020
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Zepzelca™ (lurbinectedin) was added by the National Comprehensive Cancer Network (NCCN®) to the Clinical Practice Guidelines in Oncology
Did Hedge Funds Make The Right Call On Jazz Pharmaceuticals Plc (JAZZ)?
11:29pm, Saturday, 11'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
Zogenix: Market Reaction To Fintepla's Approval Offers A Gift To Investors
01:38pm, Tuesday, 30'th Jun 2020
The weak market on Friday and day traders not getting paid immediately caused Zogenix shares to trade down after FDA approval of Fintepla®. Black box not news.
Nasdaq's $1.2 trln biotech index draws Europe's COVID drug hunters
01:31pm, Tuesday, 30'th Jun 2020
Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its therapies
BofA Raises Jazz Pharma Estimates After Zepzelca Update
06:19pm, Thursday, 18'th Jun 2020
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) provided encouraging updates on its commercial efforts in a recent conference call on the lung cancer drug Zepzelca, according to BofA Securities.The Jazz Pharm
Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval
02:15pm, Tuesday, 16'th Jun 2020
FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.
Jazz Pharmaceuticals (JAZZ) in Focus: Stock Moves 5.6% Higher
12:33pm, Tuesday, 16'th Jun 2020
Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Jazz Pharma Scores Surprise Early Approval For Lung Cancer Treatment
08:46am, Tuesday, 16'th Jun 2020
Jazz Pharmaceuticals (JAZZ) and partner PharmaMar have announced a surprise early approval from the US FDA for its Zepzelca treatment for adults with metastatic small cell lung cancer (SCLC) with dise
